ArticleJournal of gastrointestinal oncology2026
CCL5 promotes colon cancer progression via PI3K/AKT signaling and is negatively regulated by STAT1.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression.Journal of gastrointestinal oncology · 2026Article
- Cytokine and chemokine networks in colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colon cancer (CC) and rectal cancer rank third in incidence, affecting millions of individuals globally. The immune-modulatory function of CCL5 in CC is the main focus of current research, and little is known about its tumor-intrinsic processes. There is a lack of systematic research on the regulatory link between STAT1 and CCL5 in CC. This study aimed to investigate the dual functions of CCL5 and its STAT1-mediated regulation in CC progression, and to elucidate the underlying molecular mechanisms. Methods: This study combines retrospective clinical observation with experimental research. Postoperative paraffin-embedded tissues were collected from 40 colorectal cancer (CRC) patients through convenience sampling. Immunohistochemistry was employed to detect CCL5 protein expression, followed by semi-quantitative scoring. Bioinformatics analysis was conducted using public databases [The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx)]. In the experimental research, common CRC cell lines were selected, and CCL5 overexpression/knockdown models were established via lentiviral infection. Cell functions were assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR), Cell Counting Kit-8 (CCK-8), Transwell, and scratch assays. Transcriptome sequencing was performed to screen differentially expressed genes (DEGs) and pathways. The regulatory role of STAT1 was validated through dual-luciferase reporter assays. Subcutaneous tumor xenograft models in nude mice were utilized to observe Results: Compared to paracancerous tissues, the expression of CCL5 is significantly downregulated in malignant tumor tissues. Further analysis within the tumor patient cohort revealed that CCL5 expression levels are positively correlated with the degree of tumor differentiation-specifically, higher in well-differentiated tumors and lower in poorly differentiated ones. More importantly, survival analysis demonstrated that patients with high CCL5 expression have a significantly longer overall survival than those with low expression. Conclusions: We discovered through both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.